<DOC>
	<DOCNO>NCT00370513</DOCNO>
	<brief_summary>Liver cancer good target anti-angiogenic treatment pazopanib . The effect pazopanib patient liver cancer unknown . This study design evaluate safety , tolerability best dose pazopanib give patient liver cancer .</brief_summary>
	<brief_title>A Phase I Study Pazopanib Adult Patients With Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Diagnosis advance liver cancer adequate bone marrow , liver kidney function Any local therapy tumor must complete least 4 week prior enrol study Exclusion criterion : Pregnant breastfeed Any serious unstable medical psychiatric condition History metastasis central nervous system History ulcer , inflammatory bowel disease disease gut History HIV , uncontrolled infection Have cardiac condition stoke past 6 month High blood pressure Have blood clot past 6 month History bleed blood vessel</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>liver cancer</keyword>
	<keyword>pazopanib</keyword>
	<keyword>hepatocellular cancer</keyword>
</DOC>